Article Summary
李 艳,张 玮,罗 兰,李素芬,蒲爱民,吴玲姣.金刚藤联合妇科千金片对慢性盆腔炎患者血液流变学和炎症因子的影响[J].现代生物医学进展英文版,2020,(11):2072-2075.
金刚藤联合妇科千金片对慢性盆腔炎患者血液流变学和炎症因子的影响
Effect of Smilax China and Gynecological Qianjin Tablets on Hemorheology and Inflammatory Factors in Patients with Chronic Pelvic Inflammatory Disease
Received:November 05, 2019  Revised:November 28, 2019
DOI:10.13241/j.cnki.pmb.2020.11.014
中文关键词: 金刚藤  妇科千金片  慢性盆腔炎  血液流变学  炎症因子
英文关键词: Smilax china  Gynecological qianjin tablets  Chronic pelvic inflammatory disease  Hemorheology  Inflammatory factors
基金项目:四川省教育厅科研项目(18ZA0165)
Author NameAffiliationE-mail
LI Yan Department of Obstetrics and Gynecology, Xinqiao Hospital Affiliated to Military Medical University, Chongqing, 400037, China 448402424@qq.com 
ZHANG Wei Department of Obstetrics and Gynecology, People's Hospital of Chongqing High-tech District, Chongqing, 400039, China  
LUO Lan Department of Obstetrics and Gynecology, Chongqing Fourth People's Hospital, Chongqing, 400014, China  
LI Su-fen Department of Obstetrics and Gynecology, Xinqiao Hospital Affiliated to Military Medical University, Chongqing, 400037, China  
PU Ai-min Department of Obstetrics and Gynecology, Xinqiao Hospital Affiliated to Military Medical University, Chongqing, 400037, China  
WU Ling-jiao Department of Obstetrics and Gynecology, First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, 610500, China  
Hits: 845
Download times: 602
中文摘要:
      摘要 目的:研究金刚藤联合妇科千金片对慢性盆腔炎(CPID)患者血液流变学和炎症因子的影响。方法:选择从2016年2月到2019年5月在我院接受治疗的CPID患者204例进行研究。依照随机数字表法将患者划分为观察组以及对照组各102例,对照组患者予以妇科千金片治疗,观察组患者在此基础上另予以金刚藤治疗,两组均治疗6周,对比两组的疗效、临床指标、血液流变学指标以及炎症因子的水平。结果:观察组的痊愈率、总有效率均分别高于对照组,观察组的无效率低于对照组,差异均有统计学意义(P<0.05)。观察组体温恢复时间、腹痛消失时间、抗生素应用时间以及住院时间均短于对照组(P<0.05)。治疗后两组的低切全血黏度、高切全血黏度、血浆黏度(PV)、纤维蛋白原(FIB)水平均明显低于治疗前,且观察组较对照组降低(P<0.05)。治疗后两组的白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、粒-巨噬细胞集落刺激因子(GM-CSF)及C反应蛋白(CRP)水平均明显低于治疗前,且观察组较对照组降低(P<0.05)。结论:CPID患者给予金刚藤及妇科千金片联合治疗可明显改善临床指标,且有助于其机体内血液流变学及炎症症状的改善,值得临床推广应用。
英文摘要:
      ABSTRACT Objective: To study the effect of smilax china and gynecological qianjin tablets on hemorheology and inflammatory factors in patients with chronic pelvic inflammatory disease (CPID). Methods: 204 patients with CPID who were received treated in our hospital from February 2016 to May 2019 were selected to carry out research. The patients were divided into the observation group and the control group according to the random number table method, 102 cases in each group. The patients in the control group were treated with gynecological qianjin tablets, on the basis of this, the patients in the observation group was treated with smilax china, and the two groups were treated for 6 weeks. The effects, clinical indexes, hemorheological indexes and the levels of inflammatory factors were compared between the two groups. Results: The cure rate and total effective rate of the observation group were higher than those of the control group, and the inefficiency of the observation group was lower than that of the control group, with statistical significance (P<0.05).The temperature recovery time, abdominal pain disappearance time, antibiotic application time and hospitalization time in the observation group were significantly less than those in the control group (P<0.05). After treatment, the levels of low shear whole blood viscosity, high shear whole blood viscosity, plasma viscosity(PV), fibrinogen (FIB) of two groups were significantly lower than before treatment, and the observation group was lower than control group (P<0.05). After treatment, the levels of interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α(TNF-α), granulocyte-macrophage colony-stimulating factor(GM-CSF) and C reactive protein (CRP) of two groups were significantly lower than before treatment, and the observation group was lower than control group (P<0.05). Conclusion: The combined treatment of CPID patients with smilax china and gynecological qianjin tablets can can significantly improve clinical indicators, it also helps to improve hemorheology and inflammatory symptoms in the body, which is worthy of clinical application.
View Full Text   View/Add Comment  Download reader
Close